Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BioBay, Roche and Harvard Form Novel Cancer Drug Partnership

publication date: Oct 24, 2011
BioBay, the Suzhou life science park, announced a drug research collaboration with Roche and Harvard University. Harvard scientists will contribute a novel research approach to the project for a cancer drug that is built around autophagy, the degradation of cell components. BioBay will add expertise in medicinal chemistry and preclinical development, and Roche will provide access to its drug discovery, development and commercialization capabilities. The project will be implemented and managed by the newly established Nimbus Innoworks, a joint-venture between BioBay and Wen Associates. More details....

Stock Symbol: (SIX: ROG)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China